Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The Australian and Stockhead, outlining the Company’s deep pipeline.
- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)